Compare IVVD & MAGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVVD | MAGN |
|---|---|---|
| Founded | 2020 | 1864 |
| Country | United States | United States |
| Employees | N/A | 8500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.1M | 397.3M |
| IPO Year | 2021 | N/A |
| Metric | IVVD | MAGN |
|---|---|---|
| Price | $1.22 | $11.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $8.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.8M | 374.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | $5.37 |
| Revenue Next Year | $41.42 | $3.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $7.82 |
| 52 Week High | $3.07 | $15.52 |
| Indicator | IVVD | MAGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 58.76 |
| Support Level | $1.17 | $10.58 |
| Resistance Level | $1.41 | $11.44 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 36.89 | 92.13 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.